Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Other Accumulated Expenses: 2019-2025

Historic Other Accumulated Expenses for Harmony Biosciences Holdings (HRMY) over the last 5 years, with Sep 2025 value amounting to $1.8 million.

  • Harmony Biosciences Holdings' Other Accumulated Expenses fell 84.47% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 84.47%. This contributed to the annual value of $5.7 million for FY2024, which is 27.38% down from last year.
  • As of Q3 2025, Harmony Biosciences Holdings' Other Accumulated Expenses stood at $1.8 million, which was down 39.79% from $3.1 million recorded in Q2 2025.
  • Harmony Biosciences Holdings' Other Accumulated Expenses' 5-year high stood at $25.1 million during Q1 2024, with a 5-year trough of $510,000 in Q3 2021.
  • For the 3-year period, Harmony Biosciences Holdings' Other Accumulated Expenses averaged around $9.5 million, with its median value being $7.8 million (2023).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 467.91% in 2023, then plummeted by 84.47% in 2025.
  • Quarterly analysis of 5 years shows Harmony Biosciences Holdings' Other Accumulated Expenses stood at $1.4 million in 2021, then climbed by 19.41% to $1.6 million in 2022, then skyrocketed by 380.91% to $7.8 million in 2023, then decreased by 27.38% to $5.7 million in 2024, then crashed by 84.47% to $1.8 million in 2025.
  • Its Other Accumulated Expenses was $1.8 million in Q3 2025, compared to $3.1 million in Q2 2025 and $19.9 million in Q1 2025.